BiTE® Immunotherapy: The Next Generation of Cancer Treatment

Amgen Oncology is leading the development of novel therapies that specifically harness the body’s T cells, pioneering the first immuno-oncology program using a BiTE®, or bispecific T cell engager.
Amgen Oncology:
www.amgenoncology.com/
Explore the world of BiTE® immunotherapy as Amgen scientists Dr. Dirk Nagorsen and Dr. Peter Kufer discuss the current cancer treatment landscape, explain how BiTE® works and offer a preview of how Amgen is bringing this technology into the future of cancer treatment.
In the last few years, cancer treatments have taken a huge step forward, with numerous drugs being approved by various regulatory agencies. These treatments are fueled by progress in immuno-oncology, using the body's own defenses to fight cancer.
Find Amgen on the Web:
Facebook: bit.ly/35Xf09E
Instagram: bit.ly/2SYnTKJ
Twitter: bit.ly/2SW2cLq
LinkedIn: bit.ly/2xWbS17